TransThera Expects Wider China Rollout of Cancer Drug Yochanra; Shares Down 7%

MT Newswires Live10-22

TransThera Sciences (Nanjing) (HKG:2617) expects Sinopharm Holding Jiangsu to help bring its cancer drug, Yochanra, to pharmacies across 21 Chinese provinces, municipalities, and autonomous regions going forward, according to a Hong Kong bourse filing Thursday.

The announcement comes as patients recently received Yochanra on prescription in Beijing, Shanghai, Guangdong, and Jiangsu, following the company's maiden batch shipment of the drug on Sept. 17.

Shares were last down 6.6% in midday trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment